The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Norepinephrine: The redheaded stepchild of Parkinson's disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Glowinski, J., & Iversen, L. L. (1966) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1966.tb09873.x · Cited by 5,406
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807
Conner, J. M., Lauterborn, J. C., Yan, Q., Gall, C. M., & Varon, S. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-07-02295.1997 · Cited by 1,097
Zarow, C., Lyness, S. A., Mortimer, J. A., & Chui, H. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.337 · Cited by 1,002
Where Does Parkinson Disease Pathology Begin in the Brain?
Del Tredici, K., Rüb, U., de Vos, R. A. I., Bohl, J. R. E., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.5.413 · Cited by 773
Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic
Zhou, Q.-Y., & Palmiter, R. D. (1995) · Cell · doi:10.1016/0092-8674(95)90145-0 · Cited by 731
Biochemistry of Catecholamines
Molinoff, P. B., & Axelrod, J. (1971) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.40.070171.002341 · Cited by 559
Fornai, F., Schlüter, O. M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C. L., Pontarelli, F., Battaglia, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409713102 · Cited by 526
Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission
Hein, L., Altman, J. D., & Kobilka, B. K. (1999) · Nature · doi:10.1038/46040 · Cited by 520
Disease‐specific patterns of locus coeruleus cell loss
German, D. C., Manaye, K. F., White, C. L., Woodward, D. J., McIntire, D. D., Smith, W. K., Kalaria, R. N., & Mann, D. M. A. (1992) · Annals of Neurology · doi:10.1002/ana.410320510 · Cited by 512
Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery
Lee, V. M.-Y., & Trojanowski, J. Q. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.026 · Cited by 479
Noradrenaline is essential for mouse fetal development
Thomas, S. A., Matsumoto, A. M., & Palmiter, R. D. (1995) · Nature · doi:10.1038/374643a0 · Cited by 462
Noradrenergic mechanisms in neurodegenerative diseases: a theory
Marien, M. R., Colpaert, F. C., & Rosenquist, A. C. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.02.002 · Cited by 414
Sulzer, D., Bogulavsky, J., Larsen, K. E., Behr, G., Karatekin, E., Kleinman, M. H., Turro, N., Krantz, D., Edwards, R. H., Greene, L. A., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.22.11869 · Cited by 407
de la Fuente-Fernandez, R. (2004) · Brain · doi:10.1093/brain/awh290 · Cited by 402
McCoy, M. K., Martinez, T. N., Ruhn, K. A., Szymkowski, D. E., Smith, C. G., Botterman, B. R., Tansey, K. E., & Tansey, M. G. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1504-06.2006 · Cited by 354
Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys
Forno, L. S., Langston, J. W., DeLanney, L. E., Irwin, I., & Ricaurte, G. A. (1986) · Annals of Neurology · doi:10.1002/ana.410200403 · Cited by 350
Loss of locus coeruleus neurons and reduced startle in parkin null mice
von Coelln, R., Thomas, B., Savitt, J. M., Lim, K. L., Sasaki, M., Hess, E. J., Dawson, V. L., & Dawson, T. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401297101 · Cited by 347
Role of cytokines in inflammatory process in Parkinson’s disease
Sawada, M., Imamura, K., & Nagatsu, T. (2006) · Parkinson’s Disease and Related Disorders · doi:10.1007/978-3-211-45295-0_57 · Cited by 331
Madras, B. K., Xie, Z., Lin, Z., Jassen, A., Panas, H., Lynch, L., Johnson, R., Livni, E., Spencer, T. J., Bonab, A. A., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106583 · Cited by 326
Gene targeting — homing in on α2-adrenoceptor-subtype function
MacDonald, E., Kobilka, B. K., & Scheinin, M. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01063-8 · Cited by 310
Heneka, M. T., Ramanathan, M., Jacobs, A. H., Dumitrescu-Ozimek, L., Bilkei-Gorzo, A., Debeir, T., Sastre, M., Galldiks, N., Zimmer, A., Hoehn, M., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4236-05.2006 · Cited by 305
Novel pharmacological targets for the treatment of Parkinson's disease
Schapira, A. H. V., Bezard, E., Brotchie, J., Calon, F., Collingridge, G. L., Ferger, B., Hengerer, B., Hirsch, E., Jenner, P., Novère, N. L., et al. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2087 · Cited by 298
Grenhoff, J., Nisell, M., Ferr�, S., Aston-Jones, G., & Svensson, T. H. (1993) · Journal of Neural Transmission · doi:10.1007/bf01244934 · Cited by 292
Zabetian, C. P., Anderson, G. M., Buxbaum, S. G., Elston, R. C., Ichinose, H., Nagatsu, T., Kim, K.-S., Kim, C.-H., Malison, R. T., Gelernter, J., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318198 · Cited by 268
Heneka, M. T., Galea, E., Gavriluyk, V., Dumitrescu-Ozimek, L., Daeschner, J., O'Banion, M. K., Weinberg, G., Klockgether, T., & Feinstein, D. L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02434.2002 · Cited by 259
Neurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.139 · Cited by 257
Pathophysiology of Parkinson's Disease: The MPTP Primate Model of the Human Disorder
WICHMANN, T., & DeLONG, M. R. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07477.x · Cited by 255
Cenci, M. A., Kalén, P., Mandel, R. J., & Björklund, A. (1992) · Brain Research · doi:10.1016/0006-8993(92)90711-h · Cited by 223
Sriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I., & O'Callaghan, J. P. (2006) · The FASEB Journal · doi:10.1096/fj.05-5106com · Cited by 222
Noradrenergic regulation of inflammatory gene expression in brain
Feinstein, D. L., Heneka, M. T., Gavrilyuk, V., Russo, C. D., Weinberg, G., & Galea, E. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(02)00049-9 · Cited by 222
Mori, K., Ozaki, E., Zhang, B., Yang, L., Yokoyama, A., Takeda, I., Maeda, N., Sakanaka, M., & Tanaka, J. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00211-3 · Cited by 215
Swanson, C. J., Perry, K. W., Koch-Krueger, S., Katner, J., Svensson, K. A., & Bymaster, F. P. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.11.022 · Cited by 214
Mavridis, M., Degryse, A.-D., Lategan, A. J., Marien, M. R., & Colpaert, F. C. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90345-o · Cited by 211
Forno, L. S., DeLanney, L. E., Irwin, I., & Langston, J. W. (1993) · PubMed · Cited by 207
Tillerson, J. L., Caudle, W. M., Reverón, M. E., & Miller, G. W. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8021 · Cited by 191
Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area
Grenhoff, J., & Svensson, T. H. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90351-h · Cited by 190
Restoration of Norepinephrine and Reversal of Phenotypes in Mice Lacking Dopamine β‐Hydroxylase
Thomas, S. A., Marck, B. T., Palmiter, R. D., & Matsumoto, A. M. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70062468.x · Cited by 186
Xu, Z.-Q. D., Shi, T.-J. S., & H�kfelt, T. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980309)392:2<227::aid-cne6>3.0.co;2-4 · Cited by 186
Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice
Gainetdinov, R. R., Fumagalli, F., Wang, Y., Jones, S. R., Levey, A. I., Miller, G. W., & Caron, M. G. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70051973.x · Cited by 178
Noradrenaline provides long‐term protection to dopaminergic neurons by reducing oxidative stress
Troadec, J., Marien, M. R., Darios, F. D., Hartmann, A., Ruberg, M., Colpaert, F. C., & Michel, P. P. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00556.x · Cited by 174
Functional Evidence that BDNF Is an Anterograde Neuronal Trophic Factor in the CNS
Fawcett, J. P., Bamji, S. X., Causing, C. G., Aloyz, R., Ase, A. R., Reader, T. A., McLean, J. H., & Miller, F. D. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-08-02808.1998 · Cited by 172
Sallinen, J., Link, R. E., Haapalinna, A., Viitamaa, T., Kulatunga, M., Sjöholm, B., Macdonald, E., Pelto-Huikko, M., Leino, T., Barsh, G. S., et al. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.1.36 · Cited by 172
Castren, E., Thoenen, H., & Lindholm, D. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00386-j · Cited by 169
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat
COLPAERT, F. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90110-9 · Cited by 169
Norepinephine transporter inhibitors and their therapeutic potential
Zhou, J. (2004) · Drugs of the Future · doi:10.1358/dof.2004.029.12.855246 · Cited by 164
PATHOLOGICAL BASIS FOR NEUROTRANSMITTER CHANGES IN PARKINSON'S DISEASE
MANN, D. M. A., & YATES, P. O. (1983) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1983.tb00320.x · Cited by 164
Striatal synaptic plasticity: Implications for motor learning and Parkinson's disease
Pisani, A., Centonze, D., Bernardi, G., & Calabresi, P. (2005) · Movement Disorders · doi:10.1002/mds.20394 · Cited by 164
Savola, J., Hill, M. P., Engström, M., Merivuori, H., Wurster, S., McGuire, S. G., Fox, S. H., Crossman, A. R., & Brotchie, J. M. (2003) · Movement Disorders · doi:10.1002/mds.10464 · Cited by 159
Mitchell, I., Cross, A. J., Sambrook, M. A., & Crossman, A. R. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90424-0 · Cited by 157
Galanin acts as a neuroprotective factor to the hippocampus
Elliott‐Hunt, C. R., Marsh, B., Bacon, A., Pope, R. J. P., Vanderplank, P. A., & Wynick, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0304823101 · Cited by 156
Sun, M., Kong, L., Wang, X., Lu, X.-G., Gao, Q., & Geller, A. I. (2005) · Brain Research · doi:10.1016/j.brainres.2005.05.072 · Cited by 154
Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP
Seniuk, N. A., Tatton, W. G., & Greenwood, C. E. (1990) · Brain Research · doi:10.1016/0006-8993(90)91055-l · Cited by 153
Ross, R. A., & Reis, D. J. (1974) · Brain Research · doi:10.1016/0006-8993(74)91016-6 · Cited by 152
Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
Rascol, O., Arnulf, I., Paul, H. P., Brefel‐Courbon, C., Vidailhet, M., Thalamas, C., Bonnet, A. M., Descombes, S., Bejjani, B.-P. W., Fabre, N., et al. (2001) · Movement Disorders · doi:10.1002/mds.1143 · Cited by 149
Liu, J., & Mori, A. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1189 · Cited by 143
Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons
O’Meara, G. F., Coumis, U., Ma, S. Y., Kehr, J., Mahoney, S., Bacon, A., Allen, S. J., Holmes, F. E., Kahl, U., Wang, F. H., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.210254597 · Cited by 131
Schank, J. R., Ventura, R., Puglisi‐Allegra, S., Alcaro, A., Cole, C. D., Liles, L. C., Seeman, P. M., & Weinshenker, D. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301000 · Cited by 129
Self-citationNuman, S., Lane-Ladd, S. B., Zhang, L., Lundgren, K. H., Russell, D., Seroogy, K. B., & Nestler, E. J. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-24-10700.1998 · Cited by 124
Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a probabilistic model
de la Fuente‐Fernández, R., Schulzer, M., Mak, E., Calne, D. B., & Stoessl, A. J. (2004) · Brain · doi:10.1093/brain/awh102 · Cited by 123
Lategan, A. J., Marien, M. R., & Colpaert, F. C. (1990) · Brain Research · doi:10.1016/0006-8993(90)91646-x · Cited by 123
Behavioral and neurochemical characterization of α2A-adrenergic receptor knockout mice
Lähdesmäki, J., Sallinen, J., MacDonald, E., Kobilka, B. K., Fagerholm, V., & Scheinin, M. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00185-9 · Cited by 119
I. MPTP neurotoxicity: An overview and characterization of phases of toxicity
Langston, J. W. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90059-1 · Cited by 119
Targeted inactivation of the gene encoding the mouse alpha 2c-adrenoceptor homolog.
Link, R. E., Stevens, M. E., Kulatunga, M., Scheinin, M., Barsh, G. S., & Kobilka, B. K. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10044-8 · Cited by 119
Liang, C., Nelson, O. L., Yazdani, U., Pasbakhsh, P., & German, D. C. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.20098 · Cited by 117
Gerfen, C. R. (2003) · The Neuroscientist · doi:10.1177/1073858403255839 · Cited by 111
Inflammation in the nervous system. Basic mechanisms and immunological concepts.
Lassmann, H., Zimprich, F., Rössler, K., et al. (1991) · PubMed · Cited by 103
Srinivasan, J., & Schmidt, W. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02684.x · Cited by 103
Fornai, F., Alessandri, M., Torracca, M. T., Bassi, L., & Corsini, G. U. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37011-9 · Cited by 102
Rousselet, E., Joubert, C., Callebert, J., Parain, K., Tremblay, L., Orieux, G., Launay, J., Cohen‐Salmon, C., & Hirsch, É. C. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00108-6 · Cited by 98
Bourdélat-Parks, B. N., Anderson, G. M., Donaldson, Z. R., Weiss, J. M., Bonsall, R. W., Emery, M., Liles, L. C., & Weinshenker, D. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0139-8 · Cited by 97
Self-citationAdrenergic receptors in Parkinson's disease
Cash, R., Ruberg, M., Raisman‐Vozari, R., & Agid, Y. (1984) · Brain Research · doi:10.1016/0006-8993(84)90117-3 · Cited by 97
Bing, G., Zhang, Y., Watanabe, Y., McEwen, B. S., & Stone, E. A. (1994) · Brain Research · doi:10.1016/0006-8993(94)90534-7 · Cited by 96
Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice
Marien, M. R., Briley, M., & Colpaert, F. C. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90489-5 · Cited by 92
Noradrenoceptor antagonism with idazoxan improves l-dopa-induced dyskinesias in MPTP monkeys
Grondin, R., Tahar, A. H., Doan, V. D., Ladure, P., & Bédard, P. J. (2000) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002109900167 · Cited by 91
Liprando, L. A., Miner, L. H., Blakely, R., Lewis, D. A., & Sesack, S. R. (2004) · Synapse · doi:10.1002/syn.20023 · Cited by 90
Bowser, R. P., Kordower, J. H., & Mufson, E. J. (1997) · Brain Pathology · doi:10.1111/j.1750-3639.1997.tb01058.x · Cited by 90
Lategan, A. J., Marien, M. R., & Colpaert, F. C. (1992) · Life Sciences · doi:10.1016/0024-3205(92)90093-5 · Cited by 86
The effect of depression on motor function and disease severity of Parkinson's disease
Papapetropoulos, S., Ellul, J., Argyriou, A. A., Chroni, E., & Lekka, N. P. (2005) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2005.08.002 · Cited by 86
Reduced MPTP toxicity in noradrenaline transporter knockout mice
Rommelfanger, K. S., Weinshenker, D., & Miller, G. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02785.x · Cited by 77
Self-citationINSIGHTS FROM IN VIVO MODIFICATION OF ADRENERGIC RECEPTOR GENE EXPRESSION
Rohrer, D. K., & Kobilka, B. K. (1998) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.351 · Cited by 76
Effect of Reboxetine on Depression in Parkinson’s Disease Patients
Lemke, M. R. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0405 · Cited by 74
Yavich, L., Jäkälä, P., & Tanila, H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04098.x · Cited by 73
Donaldson, I., DOLPHIN, A. C., Jenner, P. G., et al. (1976) · European Journal of Pharmacology · doi:10.1016/0014-2999(76)90126-6 · Cited by 67
Traver, S., Salthun-Lassalle, B., Marien, M. R., Hirsch, É. C., Colpaert, F. C., & Michel, P. P. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.007864 · Cited by 65
A Golgi study of human locus coeruleus in normal brains and in Parkinson's disease
Patt, S., & Gerhard, L. (1993) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1993.tb00480.x · Cited by 64
Catecholamines inhibit microglial nitric oxide production
Chang, J. Y., & Liu, L.-Z. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00291-4 · Cited by 64
Dopamine beta-hydroxylase deficiency
Sénard, J., & Rouet, P. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-7 · Cited by 63
alpha2C adrenoceptors inhibit adenylyl cyclase in mouse striatum: potential activation by dopamine.
Zhang, W., Klimek, V., Farley, J. T., Zhu, M., & Ordway, G. A. (1999) · PubMed · Cited by 63
Clonidine regularizes substantia nigra dopamine cell firing
Grenhoff, J., & Svensson, T. H. (1988) · Life Sciences · doi:10.1016/0024-3205(88)90500-0 · Cited by 61
α2-Adrenergic control of dopamine overflow and metabolism in mouse striatum
Yavich, L., Lappalainen, R. I., Sirviö, J., Haapalinna, A., & MacDonald, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01375-7 · Cited by 60
PET Imaging of Norepinephrine Transporters
Ding, Y., Lin, K., & Logan, J. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778559687 · Cited by 59
Gobert, A., Billiras, R., Cistarelli, L., & Millan, M. J. (2004) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2004.04.040 · Cited by 58
A functional polymorphism regulating dopamine β‐hydroxylase influences against Parkinson's disease
Healy, D. G., Abou‐Sleiman, P. M., Ozawa, T., Lees, A. J., Bhatia, K. P., Ahmadi, K. R., Wüllner, U., Berciano, J., Möller, J. C., Kamm, C., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20063 · Cited by 54
Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo
Weinshenker, D., White, S. S., Javors, M. A., Palmiter, R. D., & Szot, P. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02889-5 · Cited by 52
Self-citationTanila, H., Mustonen, K., Sallinen, J., Scheinin, M., & Riekkinen, P. J. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00464.x · Cited by 52
van Vliet, S. A. M., Vanwersch, R. A. P., Jongsma, M. J., van der Gugten, J., Olivier, B., & Philippens, I. H. C. H. M. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00011 · Cited by 52
CART peptides colocalize with tyrosine hydroxylase neurons in rat locus coeruleus
Koylu, E. O., Smith, Y., Couceyro, P. R., & Kuhar, M. J. (1999) · Synapse · doi:10.1002/(sici)1098-2396(19990315)31:4<309::aid-syn10>3.0.co;2-6 · Cited by 51
MILLER, M. A., Kolb, P. E., Leverenz, J. B., Peskind, E. R., & Raskind, M. A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.02028.x · Cited by 50
Hein, L., Limbird, L. E., Eglen, R. M., & Kobilka, B. K. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb09368.x · Cited by 48
Treatment of advanced Parkinson’s disease
Diamond, A. L., & Jankovic, J. J. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.8.1181 · Cited by 47
Reduced MPTP neurotoxicity in striatum of the mutant mousetottering
Kilbourn, M. R., Sherman, P. S., & Abbott, L. C. (1998) · Synapse · Cited by 44
Callado, L. F., & Stamford, J. A. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742350.x · Cited by 42
German, D. C., Liang, C., Manaye, K. F., Lane, K. B., & Sonsalla, P. K. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00385-7 · Cited by 41
Pintor, L., Baillés, E., Valldeoriola, F., Tolosa, E. S., Martı́, M. J., & de Pablo, J. (2005) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2005.07.005 · Cited by 39
Reboxetine adjunct for partial or nonresponders to antidepressant treatment
Rubio, G., San, L., Lopez-Munoz, F. J., & Álamo, C. (2003) · Journal of Affective Disorders · doi:10.1016/j.jad.2003.08.001 · Cited by 38
Harro, J., Terasmaa, A., Eller, M., & Rinken, A. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02677-5 · Cited by 31
Interaction between dopamine -hydroxylase and interleukin genes increases Alzheimer's disease risk
Mateo, I., Infante, J., Rodríguez, E., Berciano, J., Combarros, O., & Llorca, J. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.075358 · Cited by 30
Noradrenergic Drugs for Levodopa-Induced Dyskinesia
Colosimo, C., & Craus, A. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200311000-00008 · Cited by 27
Fornai, F., Alessandri, M., Fascetti, F., Vaglini, F., & Corsini, G. U. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65020704.x · Cited by 25
Jin, S., Kim, H. J. T., Harris, D. C., & THOMAS, S. A. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.20263 · Cited by 23
Postnatal development of preproenkephalin mRNA containing neurons in the rat lower brainstem
Morita, Y., Zhang, J., Hironaka, T., et al. (1990) · The Journal of Comparative Neurology · doi:10.1002/cne.902920204 · Cited by 22
Noradrenaline loss selectivity exacerbates nigrostriatal toxicity in different species of rodents.
Fornai, F., Bassi, L., Bonaccorsi, I., Giorgi, F. S., & Corsini, G. U. (1997) · PubMed · Cited by 19
Cited by
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Cacabelos, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030551 · Cited by 555
Parkinson’s disease dementia: a neural networks perspective
Gratwicke, J., Jahanshahi, M., & Foltynie, T. (2015) · Brain · doi:10.1093/brain/awv104 · Cited by 435
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics
LeWitt, P. A. (2015) · Movement Disorders · doi:10.1002/mds.26082 · Cited by 391
Tay, T. L., Ronneberger, O., Ryu, S., Nitschke, R., & Driever, W. (2011) · Nature Communications · doi:10.1038/ncomms1171 · Cited by 307
Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease
Weinshenker, D. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.01.010 · Cited by 323
Self-citation
Metadata
- Authors
- Rommelfanger, K. S., & Weinshenker, D.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2007-07
- Volume
- 74
- Issue
- 2
- Pages
- 177-190
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2067590452
- Cited by
- 255
- References
- 119
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.